




FRESENIUS

At a
Glance
2022



Fresenius is a global healthcare group. We offer system-critical products and services for leading therapies for care of critically and chronically ill patients. With over 300,000 employees around the globe, and annual sales exceeding €40 billion, Fresenius is one of the world's leading healthcare companies.

The Fresenius Group comprises the Operating Companies Fresenius Kabi and Fresenius Helios and the Investment Companies Fresenius Medical Care and Fresenius Vamed.

At Fresenius, the patient always comes first. For more than 100 years now we have been working to save lives and improve the quality of life of our critically and chronically ill patients. A clear focus on innovation and efficiency has helped us to make world-class therapies accessible to a steadily increasing number of people. Yet we never get complacent about our successes, and never stop looking for better solutions. This is how Fresenius is contributing to medical progress and better patient care.

More information
is available online:
ataglance.fresenius

Our year 2022



Climate target set

Fresenius plans to halve its CO₂ emissions by 2030 on the way to becoming climate neutral by 2040.



New hospital

Work on the new main building of Helios HSK Hospital in Wiesbaden nears completion. With some 1,000 beds, it will be one of Helios' largest hospitals and one of Germany's most modern maximum care hospitals.



Expanding in biopharmaceuticals

Fresenius Kabi acquires a majority stake in mAbxience, a leading international biopharmaceuticals company based in Madrid. The takeover is a major step in expanding Fresenius Kabi's biopharmaceuticals offering as part of its Vision 2026 growth strategy.

Award for technical management

Fresenius Vamed again won the internationally renowned EFQM Global Award for its technical management of University Hospital AKH Vienna.



New CEO for Fresenius

Michael Sen takes over as CEO of Fresenius on October 1. He joined the Fresenius Group as CEO of Fresenius Kabi in April 2021.



Dialysis treatment: even in war

Showing great commitment and courage, Fresenius Medical Care employees in Ukraine treat dialysis patients even after the outbreak of war. One of three dialysis clinics is destroyed in a bombing, and another must be shut temporarily. But all patients are brought to safety, along with their families, and continue to receive treatment.




Products for critically and chronically ill patients

Key Figures in € millions	2022	2021	Growth
Sales	7,850	7,193	4%
EBIT	1,080	1,153	-14%
EBIT margin	13.8%	16.0%	
Capital expenditure/ acquisitions	1,243	533	133%
R & D expenses	629	595	6%
Employees (Dec. 31)	42,063	41,397	2%

Fresenius Kabi is a global healthcare company that specializes in **lifesaving medicines and technologies for infusion, transfusion and clinical nutrition**. The company's products and services are used for the therapy and care of critically and chronically ill patients.

Its product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. The company's clinical nutrition portfolio includes a wide selection of enteral and parenteral nutrition products. In the segment of medical technologies, Fresenius Kabi offers vital disposables, infusion pumps, apheresis machines, cell therapy devices, and more.



EVERY FOURTH BLOOD DONATION WORLDWIDE
IS COLLECTED IN A FRESENIUS KABI BLOOD BAG.

Europe's leading private hospital operator



Key Figures <small>in € millions</small>	2022	2021	Growth
Sales	11,716	10,891	7%
EBIT	1,185	1,127	5%
EBIT margin	10.1%	10.3%	
Capital expenditure/ acquisitions	642	1,021	-37%
R & D expenses	3	3	0%
Employees <small>(Dec. 31)</small>	125,700	123,484	2%

Fresenius Helios is Europe's **leading private healthcare provider**, with around 126,000 employees. Fresenius Helios includes Helios Kliniken in Germany, Quirónsalud in Spain and Latin America and the Eugin Group with a global network of reproductive clinics. Every year more than 24 million patients choose Fresenius Helios for medical treatment.

Helios operates 87 acute care hospitals, about 240 outpatient clinics, six prevention centers and 21 occupational medicine centers in Germany.

Quirónsalud operates 58 hospitals, including eight in Latin America, around 100 outpatient centers and around 300 occupational risk prevention centers.

Eugin Group's network comprises 44 clinics and 37 additional sites across 10 countries on three continents.



**AROUND 84,000 BIRTHS TAKE PLACE IN
FRESENIUS HELIOS HOSPITALS ANNUALLY.**

Products and services for individuals with renal diseases




Key Figures in € millions	2022	2021	Growth
Sales	19,398	17,619	2%
EBIT	1,817	1,915	-13%
EBIT margin	9.4%	10.9%	
Capital expenditure/ acquisitions	1,470	1,482	-1%
R & D expenses	222	221	0%
Employees (Dec. 31)	128,044	130,251	-2%

Fresenius Medical Care is the world's largest provider of **products and services** for individuals with **renal diseases** of which more than 3.9 million patients worldwide regularly undergo dialysis treatment.

Through its network of more than 4,100 dialysis clinics, Fresenius Medical Care provides dialysis treatments for over 344,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines and dialyzers.

Along with its core business, the company offers a wide variety of other healthcare services and products.



IN 2022, FRESENIUS MEDICAL CARE PROVIDED
AROUND 52 MILLION DIALYSIS TREATMENTS
TO PATIENTS.

Projects and services for healthcare facilities



Key Figures in € millions	2022	2021	Growth
Sales	2,359	2,297	2%
EBIT	20	101	-81%
EBIT margin	0.8%	4.4%	
Capital expenditure/ acquisitions	96	81	19%
Order intake	1,241	1,290	-4%
Employees (Dec. 31)	20,184	19,721	2%

Fresenius Vamed is a leading global provider of **services for hospitals and other healthcare facilities**. Its portfolio ranges from project development and planning to the total operational management of healthcare facilities and providing services to patients. The services are aimed at various areas of healthcare, ranging from prevention to acute care, rehabilitation, and nursing.

Headquartered in Vienna, Austria, Fresenius Vamed has successfully completed more than 1,000 healthcare projects in 101 countries on five continents since the company's founding in 1982.



**FRESENIUS VAMED IS RESPONSIBLE FOR THE OVERALL
OPERATIONAL MANAGEMENT OF 100 HEALTHCARE
FACILITIES WITH A TOTAL OF 15,000 BEDS.**

Employees
as of December 2022



316,920

Sales
in 2022



€40.8 billion

24%  40%
North America
Dialysis clinics: 2,671
Production sites: 10

Fresenius
Group headquarters
Bad Homburg
Germany

57%  44%
Europe
Dialysis clinics: 691
Hospitals: 137
Production sites: 45

10%  6%
**Latin America
and Africa**
Dialysis clinics: 318
Hospitals: 8
Production sites: 21

9%  10%
Asia-Pacific
Dialysis clinics: 436
Production sites: 17

Total:



Dialysis clinics: 4,116



Hospitals: 145



Production sites: 93



Sustainability



-50%

CO₂ EMISSIONS BY 2030

By the end of this decade, we want to cut our direct and indirect greenhouse gas emissions by half from the 2020 level.*

CLIMATE NEUTRAL BY 2040

We want to be climate neutral by 2040.*


OUR CLIMATE PROTECTION GOALS ARE IN LINE WITH THE MAXIMUM 1.5°C TEMPERATURE INCREASE SET OUT IN THE PARIS AGREEMENT.

* Scope 1 and 2

A commitment to operating responsibly and sustainably is part of our company's business culture, and of the way we work every day. Living up to our legal and ethical responsibilities as a globally active company is important to us.

In addition to the company's key financial indicators, since 2021 the compensation of Management Board members has also taken sustainability targets into account. Starting in 2023 we are also managing these through key performance indicators - for example, an employee survey. With this, we measure how closely employees identify with and feel connected to the company, and how committed they are to their work. In 2022, this indicator was measured globally for the first time.

THIS IS HOW SATISFIED OUR EMPLOYEES ARE WITH FRESENIUS AS AN EMPLOYER:



(Employee Engagement Index, using a 1-6 scale, with 6 as the highest possible score)



From a local pharmacy to a global corporation

1462

Opening of the Hirsch Pharmacy in Frankfurt

In the 19th century, ownership of the pharmacy passes to the Fresenius family.

1912

Founding of the company

The pharmacist Dr. Eduard Fresenius, proprietor of the Hirsch Pharmacy, establishes the pharmaceutical company Dr. E. Fresenius.



1946

Founder
Eduard Fresenius dies

1966


Distributor of dialysis machines

Fresenius starts to sell dialysis machines and dialyzers manufactured by various non-German companies.

1979

Development and sale of company's own dialysis machines

Production of the A2008 dialysis machine begins in a newly acquired factory in Schweinfurt, Germany.



1952

Else Kröner assumes management of Fresenius

The foster daughter of Eduard Fresenius will, along with her future husband Hans Kröner, build the company into a global healthcare group over the following decades.



1986

Fresenius listed on stock market

1994

Entry into project business

With the acquisition of Hospitalia International, Fresenius enters the project business to develop hospitals and other healthcare facilities.

1996

Entry into Dialysis Services

Fresenius Medical Care is created when the U.S. dialysis provider National Medical Care, acquired by Fresenius, is merged with Fresenius' own dialysis business. The project business is expanded with the acquisition of VAMED AG.



1999

Expansion of infusions business

The nutrition business of Pharmacia & Upjohn is acquired and then merged with Fresenius Pharma to form Fresenius Kabi.



2005

Expansion of hospital business

Fresenius acquires Helios, one of Germany's leading private hospital operators.

2008

Expansion in I.V. generics

Fresenius Kabi enters the North American pharmaceuticals market through the acquisition of APP Pharmaceuticals.

2017

Hospital network expands

Fresenius Helios acquires Quirónsalud, Spain's largest private hospital operator.

Move into biosimilars

Biosimilars are imitation products of biotechnologically produced drugs.

2021

Entry into reproductive medicine

Fresenius Helios takes over the Eugin Group, a leading international group in the field of fertility treatments.

2023

#FutureFresenius

Fresenius is moving ahead with a simplified structure, sharper focus and acceleration of performance.


Fresenius is a strong company, with great products, great market positions. Now we have to make it stronger.

Michael Sen, CEO



Financial Calendar 2023

Publication of 2022 business results	February 22, 2023
Results 1 st Quarter	May 9, 2023
Annual General Meeting (virtual)	May 17, 2023
Capital Markets Day	May 25, 2023
Results 2 nd Quarter	August 2, 2023
Results 3 rd Quarter	November 2, 2023



Fresenius SE & Co. KGaA

Else-Kröner-Str. 1
61352 Bad Homburg
Germany

T +49 6172 608-0

www.fresenius.com



More information: 
ataglance.fresenius

Contact for Media

Corporate Communications
T +49 6172 608-2501
pr-fre@fresenius.com

Contact for Shareholders

Investor Relations
T +49 6172 608-2487
ir-fre@fresenius.com

Contact for Job Applicants

Employer Branding
 +49 172 7407809
careers@fresenius.com



www.fresenius.com/socialmedia

Some figures adjusted for special items;
when applicable, changes are in constant currency.

